Current technological advances in magnetic resonance with critical impact for clinical diagnosis and therapy

Investigative Radiology

Volumn 48, Issue 12, 2013, Pages 869-877

  Runge, Val M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Brain; Breast; Breast carcinoma; Contrast media; Contrast enhanced MR angiography; Cryoablation; Gadolinium chelate; Imaging; Interventional MR; Kidney; Laser ablation; Liver; Magnetic resonance; Magnetic resonance angiography; Magnetic resonance imaging; MR; MR guided biopsy; MR guided focused ultrasound; MR PET; MRA; MRI; Musculoskeletal system; Neoplastic disease; PET; PET MR; Prostate; Prostate carcinoma; RF ablation; Tumor diagnosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM CHELATE;

BRAIN; BREAST; BREAST CARCINOMA; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DEVICE SAFETY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; ECHO PLANAR IMAGING; HUMAN; INTERMETHOD COMPARISON; KIDNEY FUNCTION; LIVER; LYMPHOMA; MAGNETIC RESONANCE ANGIOGRAPHY; MUSCULOSKELETAL SYSTEM; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE; PROSTHESIS LOOSENING; REVIEW; SYSTEMATIC REVIEW;

ANIMALS; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; SURGERY, COMPUTER-ASSISTED;

EID: 84888203424     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/01.rli.0000434380.71793.d3     Document Type: Review

References (92)

1. Katoh M, Haage P, Wiethoff AJ, et al. Molecular magnetic resonance imaging of deep vein thrombosis using a fibrin-targeted contrast agent: a feasibility study. Invest Radiol. 2009;44:146-150.
2. Vymazal J, Spuentrup E, Cardenas-Molina G, et al. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Invest Radiol. 2009;44:697-704.
3. Chow AM, Tan M, Gao DS, et al. Molecular MRI of liver fibrosis by a peptidetargeted contrast agent in an experimental mouse model. Invest Radiol. 2013; 48:46-54.
4. Dumas S, Jacques V, SunWC, et al. High relaxivity magnetic resonance imaging contrast agents. Part 1. Impact of single donor atom substitution on relaxivity of serum albumin-bound gadolinium complexes. Invest Radiol. 2010;45:600-612.
5. Jacques V, Dumas S, SunWC, et al. High-relaxivity magnetic resonance imaging contrast agents. Part 2. Optimization of inner- and second-sphere relaxivity. Invest Radiol. 2010;45:613-624.
6. Matson ML, Wilson LJ. Nanotechnology and MRI contrast enhancement. Future Med Chem. 2010;2:491-502.
7. Sommer CM, Stampfl U, Bellemann N, et al. Multimodal visibility (radiography, computed tomography, and magnetic resonance imaging) of microspheres for transarterial embolization tested in porcine kidneys. Invest Radiol. 2013;48:213-222.
8. Kim H-K, Jung K-H, Kang M-K, et al. DO3A-benzothiazole conjugates for use as Gd-based theragnostic agents. International Society for Magnetic Resonance in Medicine, 21st Annual Meeting & Exhibition, 22-26 April 2013, Salt Lake City, UT:1879.
9. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol. 2007;42:139-145. (Pubitemid 46104895)
10. Runge VM. Gadolinium and nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2009;192:W195YW196.
11. Haylor J, Dencausse A, Vickers M, et al. Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Invest Radiol. 2010;45:507-512.
12. Amano Y, Takahama K, Kumita S. Noncontrast-enhanced three-dimensional magnetic resonance aortography of the thorax at 3.0 T using respiratorycompensated T1-weighted k-space segmented gradient-echo imaging with radial data sampling: preliminary study. Invest Radiol. 2009;44:548-552.
13. Krishnam MS, Tomasian A, Malik S, et al. Three-dimensional imaging of pulmonary veins by a novel steady-state free-precession magnetic resonance angiography technique without the use of intravenous contrast agent: initial experience. Invest Radiol. 2009;44:447-453.
14. Lim RP, Winchester PA, Bruno MT, et al. Highly accelerated single breath-hold noncontrast thoracic MRA: evaluation in a clinical population. Invest Radiol. 2013;48:145-151.
15. Lim RP, Fan Z, Chatterji M, et al. Comparison of nonenhanced MR angiographic subtraction techniques for infragenual arteries at 1.5 T: a preliminary study. Radiology. 2013;267:293-304.
16. Lohan DG, Tomasian A, Saleh RS, et al. Ultra-low-dose, time-resolved contrastenhanced magnetic resonance angiography of the carotid arteries at 3.0 tesla. Invest Radiol. 2009;44:207-217.
17. Voth M, Haneder S, Huck K, et al. Peripheral magnetic resonance angiography with continuous table movement in combination with high spatial and temporal resolution time-resolved MRA with a total single dose (0.1 mmol/kg) of gadobutrol at 3.0 T. Invest Radiol. 2009;44:627-633.
18. Frydrychowicz A, Markl M, Hirtler D, et al. Aortic hemodynamics in patients with and without repair of aortic coarctation: in vivo analysis by 4D flowsensitive magnetic resonance imaging. Invest Radiol. 2011;46:317-325.
19. Kukuk GM, Hadizadeh DR, Bostrom A, et al. Cerebral arteriovenous malformations at 3.0 T: intraindividual comparative study of 4D-MRA in combination with selective arterial spin labeling and digital subtraction angiography. Invest Radiol. 2010;45:126-132.
20. Attenberger UI, Ingrisch M, Dietrich O, et al. Time-resolved 3D pulmonary perfusion MRI: comparison of different k-space acquisition strategies at 1.5 and 3 T. Invest Radiol. 2009;44:525-531.
21. Rapacchi S, Fei H, Natsuaki Y, et al. High spatial and temporal resolution dynamic contrast-enhanced magnetic resonance angiography (CE-MRA) using compressed sensing with magnitude image subtraction. International Society for Magnetic Resonance in Medicine, 21st Annual Meeting & Exhibition, 22-26 April 2013, Salt Lake City, UT:0542.
22. Fries P, Runge VM, Kirchin MA, et al. Diffusion-weighted imaging in patients with acute brain ischemia at 3 T: current possibilities and future perspectives comparing conventional echoplanar diffusion-weighted imaging and fast spin echo diffusion-weighted imaging sequences using BLADE (PROPELLER). Invest Radiol. 2009;44:351-359.
23. Morelli JN, RungeVM, Feiweier T, et al. Evaluation of a modified Stejskal-Tanner diffusion encoding scheme, permitting a marked reduction in TE, in diffusionweighted imaging of stroke patients at 3 T. Invest Radiol. 2010;45:29-35.
24. Attenberger UI, Runge VM, Stemmer A, et al. Diffusion weighted imaging: a comprehensive evaluation of a fast spin echo DWI sequence with BLADE (PROPELLER) k-space sampling at 3 T, using a 32-channel head coil in acute brain ischemia. Invest Radiol. 2009;44:656-661.
25. Morelli JN, Saettele MR, Rangaswamy RA, et al. Echo planar diffusion-weighted imaging: possibilities and considerations with 12- and 32-channel head coils. J Clin Imaging Sci. 2012;2:31.
26. Frost R, Jezzard P, Porter DA, et al. Simultaneous multi-slab acquisition in 3D multi-slab diffusion-weighted readout-segmented echo-planar imaging. International Society for Magnetic Resonance in Medicine, 21st Annual Meeting & Exhibition, 22-26 April 2013, Salt Lake City, UT;3176.
27. Keil B, Cohen-Adad J, Porter DA, et al. Simultaneous diffusion-weighted MRI of brain and cervical spinal cord using a 64-channel head-neck array coil at 3T. International Society for Magnetic Resonance in Medicine, 21st Annual Meeting & Exhibition, 22-26 April 2013, Salt Lake City, UT;1210.
28. Erb K, Willerding G, Taupitz M, et al. Diffusion weighted imaging of ocular melanoma. Invest Radiol. 2013;48:702-707.
29. Percy DB, Ribot EJ, Chen Y, et al. In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest Radiol. 2011;46:718-725.
30. Reichert M, Morelli JN, Runge VM, et al. Contrast-enhanced 3-dimensional SPACE versus MP-RAGE for the detection of brain metastases: considerations with a 32-channel head coil. Invest Radiol. 2013;48:55-60.
31. Kober T, Granziera C, Ribes D, et al. MP2RAGE multiple sclerosis magnetic resonance imaging at 3 T. Invest Radiol. 2012;47:346-352.
32. Ingrisch M, Sourbron S, Morhard D, et al. Quantification of perfusion and permeability in multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3T. Invest Radiol. 2012;47:252-258.
33. Muehlmann M, Koerte I, Laubender R, et al. MR-based estimation of intracranial pressure correlates with VP-shunt valve opening pressure setting in children with hydrocephalus. Invest Radiol. 2013;48:543-547.
34. Springer F, Machann J, Schwenzer NF, et al. Quantitative assessment of intrahepatic lipids using fat-selective imaging with spectral-spatial excitation and in-/opposed-phase gradient echo imaging techniques within a study population of extremely obese patients: feasibility on a short, wide-bore MR scanner. Invest Radiol. 2010;45:484-490.
35. Kuhn JP, Evert M, Friedrich N, et al. Noninvasive quantification of hepatic fat content using three-echo dixon magnetic resonance imaging with correction for T2 relaxation effects. Invest Radiol. 2011;46:783-789.
36. Kang BK, Yu ES, Lee SS, et al. Hepatic fat quantification: a prospective comparison of magnetic resonance spectroscopy and analysis methods for chemicalshift gradient echo magnetic resonance imaging with histologic assessment as the reference standard. Invest Radiol. 2012;47:368-375.
37. Tang A, Tan J, Sun M, et al. Nonalcoholic fatty liver disease:MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology. 2013;267: 422-431.
38. Riffel P, Attenberger U, Kannengiesser S, et al. Highly accelerated T1 weighted abdominal imaging using 2D CAIPIRINHA: a comparison with GRAPPA. Invest Radiol. 2013;48:554-561.
39. Michaely HJ, Morelli JN, Budjan J, et al. CAIPIRINHA-Dixon-TWIST (CDT)- volume-interpolated breathhold exam (VIBE): a new technique for fast timeresolved dynamic three-dimensional imaging of the abdomen with high spatial resolution. Invest Radiol. 2013;48:590-597.
40. Chen Y, Lee GR, Wright KL, et al. 3D high spatiotemporal resolution quantitative liver perfusion imaging using a stack-of-spirals acquisition and through-time non-cartesian GRAPPA acceleration. International Society for Magnetic Resonance in Medicine, 21st Annual Meeting & Exhibition, 22-26 April 2013, Salt Lake City, UT:601.
41. Gloviczki ML, Glockner J, Gomez SI, et al. Comparison of 1.5 and 3 T BOLD MR to study oxygenation of kidney cortex and medulla in human renovascular disease. Invest Radiol. 2009;44:566-571.
42. Prasad P, Li LP, Halter S, et al. Evaluation of renal hypoxia in diabetic mice by BOLD MRI. Invest Radiol. 2010;45:819-822.
43. Ebrahimi B, Gloviczki M, Woollard JR, et al. Compartmental analysis of renal BOLD MRI data: introduction and validation. Invest Radiol. 2012;47:175-182.
44. Morrell G, Jeong EK, Shi X, et al. Prospectively navigated multi-echo GRE sequence for improved 2D BOLD imaging of the kidneys. International Society for Magnetic Resonance in Medicine, 21st Annual Meeting & Exhibition, 22-26 April 2013, Salt Lake City, UT:1569.
45. Kang SK, Huang WC, Wong S, et al. DCE MRI measurement of renal function in patients undergoing partial nephrectomy: preliminary experience. Invest Radiol. 2013;48:687-692.
46. Notohamiprodjo M, Horng A, Pietschmann MF, et al. MRI of the knee at 3T: first clinical results with an isotropic PDfs-weighted 3D-TSE-sequence. Invest Radiol. 2009;44:585-597.
47. Ai T, Padua A, Goerner F, et al. SEMAC-VAT and MSVAT-SPACE sequence strategies for metal artifact reduction in 1.5T magnetic resonance imaging. Invest Radiol. 2012;47:267-276.
48. Sutter R, Ulbrich EJ, Jellus V, et al. Reduction of metal artifacts in patients with total hip arthroplasty with slice-encoding metal artifact correction and viewangle tilting MR imaging. Radiology. 2012;265:204-214.
49. Nittka M, Otazo R, Rybak LD, et al. Highly accelerated SEMAC metal implant imaging using joint compressed sensing and parallel imaging. International Society for Magnetic Resonance in Medicine, 21st Annual Meeting & Exhibition, 22-26 April 2013, Salt Lake City, UT:2558.
50. Pinker K, Grabner G, Bogner W, et al. A combined high temporal and high spatial resolution 3 Tesla MR imaging protocol for the assessment of breast lesions: initial results. Invest Radiol. 2009;44:553-558.
51. Pediconi F, Catalano C, Roselli A, et al. The challenge of imaging dense breast parenchyma: is magnetic resonance mammography the technique of choice? A comparative study with x-ray mammography and whole-breast ultrasound. Invest Radiol. 2009;44:412-421.
52. Sardanelli F, Podo F, Santoro F, et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrastenhanced magnetic resonance imaging (the high breast cancer risk Italian 1 study): final results. Invest Radiol. 2011;46:94-105.
53. Pediconi F, Miglio E, Telesca M, et al. Effect of preoperative breast magnetic resonance imaging on surgical decision making and cancer recurrence rates. Invest Radiol. 2012;47:128-135.
54. Baltzer P, Bogner W, Bickel H, et al. Is assessment of breast tumors with the sole use of dwi sufficient for breast cancer diagnosis? International Society for Magnetic Resonance in Medicine, 21st Annual Meeting & Exhibition, 22-26 April 2013, Salt Lake City, UT:3381.
55. Yi A, Cho N, Im SA, et al. Survival Outcomes of Breast Cancer Patients Who Receive Neoadjuvant Chemotherapy: Association with Dynamic Contrastenhanced MR Imaging with Computer-aided Evaluation. Radiology. 2013; 268:662-672.
56. Pickles MD, Manton DJ, Lowry M, et al. Prognostic value of pre-treatment DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional clinical prognostic parameters. International Society for Magnetic Resonance in Medicine, 21st Annual Meeting & Exhibition, 22-26 April 2013, Salt Lake City, UT:1728.
57. Gibbs P, Liney GP, Pickles MD, et al. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol. 2009;44:572-576.
58. Eiber M, Beer AJ, Holzapfel K, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol. 2010;45:15-23.
59. Yakar D, Hambrock T, Huisman H, et al. Feasibility of 3T dynamic contrastenhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy. Invest Radiol. 2010;45: 121-125.
60. Scheenen TW, Futterer J, Weiland E, et al. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest Radiol. 2011;46:25-33.
61. Maas MC, KoopmanMJ, Litjens GJS, et al. Prostate Cancer Localization with a Multiparametric MR Approach (PCaMAP): Initial Results of a Multi-Center Study. International Society for Magnetic Resonance in Medicine, 21st Annual Meeting & Exhibition, 22-26 April 2013, Salt Lake City, UT:1769.
62. Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, et al. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤= 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol. 2012;47:153-158.
63. Hoeks C, Vos E, Bomers J, Barentsz J, et al. Diffusion weighted MR imaging in the prostate transition zone: histopathological validation using MR guided biopsy specimens. Invest Radiol. 2013;48:693-701.
64. Somford DM, Hoeks CM, Hulsbergen-van de Kaa CA, et al. Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancer. Invest Radiol. 2013;48:152-157.
65. Nagel KN, Schouten MG, Hambrock T, et al. Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology. 2013;267:164-172.
66. Maas MC, Fuetterer JJ, Scheenen TWJ. Quantitative evaluation of computed high b value diffusion weighted magnetic resonance imaging of the prostate. Invest Radiol. 2013;48:779-786.
67. Kos S, Huegli R, Hofmann E, et al. Feasibility of real-time magnetic resonanceguided angioplasty and stenting of renal arteries in vitro and in swine, using a new polyetheretherketone-based magnetic resonance-compatible guidewire. Invest Radiol. 2009;44:234-241.
68. Kramer NA, Kruger S, Schmitz S, et al. Preclinical evaluation of a novel fiber compound MR guidewire in vivo. Invest Radiol. 2009;44:390-397.
69. Tempany CM, Stewart EA, McDannold N, et al. MR imaging-guided focused ultrasound surgery of uterine leiomyomas: a feasibility study. Radiology. 2003; 226:897-905. (Pubitemid 36259169)
70. Kim YS, Lim HK, Kim JH, et al. Dynamic contrast-enhancedmagnetic resonance imaging predicts immediate therapeutic response of magnetic resonance-guided high-intensity focused ultrasound ablation of symptomatic uterine fibroids. Invest Radiol. 2011;46:639-647.
71. Ahrar K, Ahrar JU, Javadi S, et al. Real-time magnetic resonance imagingguided cryoablation of small renal tumors at 1.5 T. Invest Radiol. 2013;48: 437-444.
72. Napoli A, Anzidei M, Cavallo Marincola B, et al. Primary pain palliation and local tumor control in bone metastases treated with magnetic resonance-guided focused ultrasound. Invest Radiol. 2013;48:351-358.
73. Trumm CG, Stahl R, Clevert DA, et al. Magnetic resonance imaging-guided focused ultrasound treatment of symptomatic uterine fibroids: impact of technology advancement on ablation volumes in 115 patients. Invest Radiol. 2013;48:359-365.
74. Rempp H, Unterberg J, Hoffmann R, et al. Therapy monitoring of magnetic resonance-guided radiofrequency ablation using T1- and T2-weighted sequences at 1.5 T: reliability of estimated ablation zones. Invest Radiol. 2013; 48:429-436.
75. Vogl TJ, Freier V, Nour-Eldin NE, et al. Magnetic resonance-guided laserinduced interstitial thermotherapy of breast cancer liver metastases and other noncolorectal cancer liver metastases: an analysis of prognostic factors for long-term survival and progression-free survival. Invest Radiol. 2013;48: 406-412.
76. Oto A, Sethi I, Karczmar G, et al. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013;267:932-940.
77. Lu Y, Fritz J, Li C, et al. MR imaging-guided percutaneous biopsy of mediastinal masses: diagnostic performance and safety. Invest Radiol. 2013;48: 452-457.
78. Kramer NA, Donker HC, Otto J, et al. A concept for magnetic resonance visualization of surgical textile implants. Invest Radiol. 2010;45:477-483.
79. Kraemer NA, Donker HC, Kuehnert N, et al. In vivo visualization of polymerbased mesh implants using conventional magnetic resonance imaging and positive-contrast susceptibility imaging. Invest Radiol. 2013;48:200-205.
80. Hansen NL, Barabasch A, Distelmaier MS, et al. First in-human MR-visualisation of surgical mesh implants for inguinal hernia treatment. Invest Radiol. 2013; 48:770-778.
81. Kwee TC, van Ufford HM, Beek FJ, et al. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol. 2009;44:683-690.
82. Lin C, Itti E, Luciani A, et al. Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: pilot study. Invest Radiol. 2011;46:341-349.
83. Schraml C, Martirosian P, Brendle C, et al. Characterization of head and neck tumors in a simultaneous whole-bodyMR/PET scanner using diffusion-weighted imaging and FDG-PET. International Society for Magnetic Resonance in Medicine, 21st Annual Meeting & Exhibition, 22-26 April 2013, Salt Lake City, UT:1230.
84. Brendle CB, Schmidt H, Fleischer S, et al. Simultaneously acquired MR/PET images compared with sequential MR/PET and PET/CT: alignment quality. Radiology. 2013;268:190-199.
85. Quick HH, von Gall C, Zeilinger M, et al. Integrated whole-body PET/MR hybrid imaging: clinical experience. Invest Radiol. 2013;48:280-289.
86. Nensa F, Poeppel TD, Beiderwellen K, et al. Hybrid PET/MR imaging of the heart: feasibility and initial results. Radiology. 2013;268:366-373.
87. Braun H, Ziegler S, Quick HH. Simultaneous PET/MR with continuous table motion: the effect of table motion speed on image quality. International Society for Magnetic Resonance in Medicine, 21st AnnualMeeting & Exhibition, 22-26 April 2013, Salt Lake City, UT:2818.
88. Aklan B, Paulus DH, Fual D, et al. Towards simultaneous PET/MR breast imaging: systematic evaluation and integration of an RF breast coil. International Society for Magnetic Resonance in Medicine, 21st Annual Meeting & Exhibition, 22-26 April 2013, Salt Lake City, UT:2813.
89. Wetter A, Lipponer C, Nensa F, et al. Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol. 2013;48:256-262.
90. Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, et al. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest Radiol. 2013;48:273-279.
91. Stolzmann P, Veit-Haibach P, Chuck N, et al. Detection rate, location, and size of pulmonary nodules in trimodality PET/CT-MR: comparison of low-dose CT and Dixon-based MR imaging. Invest Radiol. 2013;48:241-246.
92. Gaertner FC, Beer AJ, SouvatzoglouM, et al. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors. Invest Radiol. 2013;48:263-272.